Showing 6501-6510 of 23149 results for "".
The Fever: How Malaria Has Ruled Humankind for 500,000 Years
https://reachmd.com/programs/book-club/the-fever-how-malaria-rules-humankind-for-500000-years/7987/Journalist Sonia Shah sets out to answer tough questions about malaria, the global disease infecting 500 million people every year.E-cigarettes: An Emerging Public Health Challenge
https://reachmd.com/programs/grand-rounds-nation/e-cigarettes-emerging-public-health-challenge/7719/Electronic cigarettes, or e-cigarettes, are an emerging challenge for public health. These devices are part of a growing landscape of electronic nicotine delivery systems (ENDS) that includes many different types of products, such as vape pens and e-hookahs. Despite differences in appearance, theseClinical Decisions on Cardiovascular Disease: Are Risks or Causes Your Guide?
https://reachmd.com/programs/lipid-luminations/clinical-decisions-cardiovascular-disease-risks-or-causes-your-guide/7646/Risk is calculated by a variety of algorithms, all of which produce an estimate for that individual based on age, gender, cholesterol, blood pressure, and smoking history. The estimate is critical to clinical decision-making, but how accurate is it? Host Dr. Alan Brown welcomes Dr. Allan Sniderman,Dyslipidemia During Pregnancy: The Risks for Two Patients
https://reachmd.com/programs/lipid-luminations/dyslipidemia-during-pregnancy-the-risks-for-two-patients/7080/An old clinical dogma in OB/GYN was that dyslipidemia during pregnancy wouldn't have any long term implications on the developing fetus because of short exposures at 9 months. This has since been shown to be untrue. What health issues surface in children whose mothers experienced abnormally elevatedNew Horizons for ReachMD
https://reachmd.com/programs/clinicians-roundtable/new-horizons-for-reachmd/6833/Change: it's in the air at ReachMD. The word is out that a platform shift will be taking place on October 18th, where ReachMD will move from XM satellite radio to iHeart internet radio. But what does this momentous occasion mean for the ReachMD listenership community? Join host Dr. Matt Birnholz inOccipital Nerve Stimulation for Patients With Intractable Cluster Headache
https://reachmd.com/programs/focus-on-neurology-and-psychiatry/occipital-nerve-stimulation-for-patients-with-intractable-cluster-headache/4280/Occipital Nerve Stimulation has recently emerged as a novel form of therapy for patients with intractable cluster headaches. Could it be the hallmark of a new era in stimulation therapies for primary headache syndromes? Joining host Dr. Mary Leuchars to share insights on this subject is neurologistRegeneration: Science Fiction or Reality?
https://reachmd.com/programs/focus-on-future-medicine-and-genetics/regeneration-science-fiction-or-reality/4083/What are the barriers in science that keep us from reaching the lofty goal of limb and organ regeneration? Host Dr. Leslie Lundt is joined by Dr. Dennis Steindler, the Joseph J. Bagnor/Shands Professor of Medical Research and the executive director of the McKnight Brain Institute at the University oDeep Brain Stimulation for Treatment-Resistant Depression
https://reachmd.com/programs/clinicians-roundtable/deep-brain-stimulation-for-treatment-resistant-depression/3838/Standard treatments for depression are effective in providing relief in most cases. However, some individuals suffer from depression that does not diminish despite adequate trials of antidepressants, psychotherapy and even electroconvulsive therapy. There is new hope for those suffering from treatmeThe Secret History of the War on Cancer
https://reachmd.com/programs/clinicians-roundtable/the-secret-history-of-the-war-on-cancer/2694/Dr. Devra Davis tells us that more than $40 billion and 40 years have passed since the official launch of the war on cancer in this country. We remain focused on finding and curing cancer instead of controlling what causes it. Identifiable steps to significantly reduce or even eliminate many cancerTrial in Progress: Phase 3 MoonRISe-3 Study
https://reachmd.com/clinical-practice/oncology-hematology/trial-in-progress-phase-3-moonrise-3-study/33214/Dr. Neal Shore discusses the study design of the phase 3 MoonRISe-3 trial of TAR-210 in BCG-treated high-risk NMIBC with susceptible FGFR alterations.